Delivery Order SPE2DB24D3013-SPE2DB25FFQBS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,307.89 to AmerisourceBergen Drug Corp for Fycompa 0.5 mg/ml oral suspension (340ml) on July 18, 2025. This is a firm fixed price delivery order with an ultimate completion date of July 21, 2025, with performance to occur at the contractor's location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,027.44 for Fycompa 8 mg tablets (30-count) with an ultimate completion date of September 5, 2025. This competitive delivery order, issued under firm fixed-price terms with no set-aside designation, represents a single pharmaceutical supply transaction fulfilled from the contractor's place of performance in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,524.73 to AmerisourceBergen Drug Corp for the supply of Fycompa 4 mg tablets (30-count units). This firm fixed-price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition for this...
- The Defense Logistics Agency awarded a delivery order valued at $2,111.20 to AmerisourceBergen Drug Corp for the supply of Fycompa 4 mg tablets (30-count units) on July 10, 2025, with completion scheduled for July 11, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and was performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 14, 2025, valued at $1,489.87 for the supply of Fycompa 2 mg tablets (30-count packages) under a firm fixed price contract. This is a non-set-aside, competitively awarded delivery order issued by the Defense Logistics Agency's Medical Supply Chain, a component of the Department of Defense. The place of performance is listed as the contractor's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order valued at $1,580.41 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fycompa 8 mg tablets (30-count packages). This is a firm fixed price, competitively awarded delivery order with no set-aside designation and a completion date of July 22, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's place of performance. This...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $3,148.08 by the Defense Logistics Agency on August 5, 2025, for the supply of Fycompa 4 mg tablets (30-count). This firm fixed-price delivery order, which concludes on August 6, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on February 13, 2025, for the supply of Fycompa 4 mg tablets (30-count units) with a ceiling value of $1,837.44. This firm fixed-price delivery order, which is expected to be completed by February 14, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Fycompa (perampanel) is an oral anticonvulsant medication used...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Fycompa 8 mg tablets (30-count) with a ceiling value of $1,417.05. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 2, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate office location in the same...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for Fycompa 8 mg tablets (30-count units) with a ceiling value of $1,713.96. This firm fixed-price delivery order, which is expected to be completed by June 4, 2025, represents a continuation of AmerisourceBergen's significant role as a pharmaceutical supplier to the federal government. The award was made without a set-aside designation, indicating open competition. The performance location is...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQBSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for 30 tablets of Fycompa 6 mg on September 3, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. Fycompa is an antiepileptic medication used to treat partial-onset seizures, reflecting AmerisourceBergen's role as a critical pharmaceutical supplier to federal healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime contractor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, including service to the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contracts demonstrates its capability to meet diverse medical procurement requirements across multiple therapeutic domains through open competition.